JPMorgan Chase invests $2.93 billion in Eli Lilly, targeting the GLP-1 revolution and its weight-loss wave. Eli Lilly’s stock has surged, generating $19.3 billion in sales. JPMorgan’s 13F filing also reveals investments in Amphenol and S&P 500 puts, reflecting a balanced portfolio strategy amidst market highs and growth opportunities.

Read more at Yahoo Finance: JPMorgan builds $2.93 billion stake in health care stock